New Data Presented at EACS 2023 Further Demonstrate Strong C

– Two-Year Resistance Analysis from CAPELLA Pivotal Trial Reinforces Sunlenca as a Person-Centered Option in Combination with an Optimized Background Regimen –


– Latest Research Highlights...

Related Keywords

Australia , United States , Canada , Poland , Warsaw , L67 , United Arab Emirates , Japan , Foster City , California , United Kingdom , Israel , Switzerland , Jared Baeten , Informationfor Sunlenca , Gilead Sciences , Gilead Sciences Inc , Nasdaq , Exchange Commission , European Union , Clinical Development , Vice President , Year Resistance , Healthcare Professionals , Study Coordinators , Important Safety Information , Safety Information , Antiretroviral Pregnancy Registry , Funders Concerned About , Private Securities Litigation Reform Act , Quarterly Report , Prescribing Informationfor Sunlenca , Markets ,